At a glance
- What the study gets you
- Health checks and monitoring — no treatment given
- Type of study
- Observational (no treatment given)
- Time in hospital
- In-person visits at study sites — visit count not specified by the sponsor
- Drug or intervention
- Patients with inherited cardiac condition, onset <16 years old and Parents (other)
- How long the study runs
- Study runs about 51 months (dates as stated)
- About the drug or intervention
- Patients with inherited cardiac condition, onset <16 years old and Parents — other: Patients with a confirmed diagnosis of an inherited cardiac condition, onset \<16 years old and Parents will have samples that undergo whole genome sequencing and biomarker analysis
- Patient visit burden
- Not specified by the sponsor
- Type of study
- Observing health over time
- Ages
- Not specified
- Who
- All
- Number of participants
- 300
- Started
- 2022-09-01
- Last checked
- 2025-03
Plain English Summary
What is this study?
- • Testing a new treatment for inherited cardiac conditions
- • Clinical study - 300 participants
- • All patients with heart disease should have the opportunity to participate in research into their condition, to advance knowledge and treatment
Who can take part?
- • Adults
- • Diagnosed with inherited cardiac conditions
Where?
- • London - Royal Brompton Hospital
- • London - Great Ormond Street Hospital for Children
- • Uxbridge - Harefield Hospital
This is a simplified summary. Always discuss with your doctor before making any decisions.
About This Trial
All patients with heart disease should have the opportunity to participate in research into their condition, to advance knowledge and treatment. The investigators have built an online registry and database - The Heart Hive - to connect research-willing participants (with heart muscle disease) with active researchers and projects. Participants enrol and upload their own data through the website.This study uses The Heart Hive platform to study cardiomyopathies - heart muscle disease. These are progressive diseases, and there is a need to better understand what factors affect the chances of developing cardiomyopathy, and how the condition progresses. The study will collect information about participants diagnosis, DNA for genetic analysis, and then follow participants' clinical progress. The study will identify genetic variants that cause cardiomyopathy, and determine which specific genetic or environmental factors predict disease severity, progression and response to treatment, with an overall objective of identifying new and personalised treatments for patients with this disease.
More detail
This is a multi-centre, observational study of children with rare inherited cardiac conditions. The focus of the study will be on children with clinically diagnosed cardiomyopathy and their unaffected parents, with collection of baseline demographic data, imaging data, and genotyping data. Children and their parents will been rolled over a 5-year period. Sub-sets of patients with confirmed diagnoses of other heritable cardiovascular diseases with onset \<16 years will also be recruited.These will include children who following evaluation by their clinical multidisciplinary team (which will include a geneticist or genetic counsellor) are likely to have a rare monogenic condition. Other affected family members of eligible patients may be also invited to participate in the study. Information for this study will be collected primarily from investigations performed as part of the participants' routine clinical care including whole genome sequencing commissioned by NHS England. The study will seek consent to access and export this data. Procedures performed as part of this study may include venepuncture and/or saliva collection and carry minimal risk to the patient. Parents of participants that are recruited into the study will donate a blood sample (or saliva sample if unable to provide blood) and consent will be requested for collection of health information and results of relevant investigations carried out as part of their routine clinical care (e.g. an echocardiogram). Other family members that are recruited into the study will donate a blood sample (or saliva sample if unable to provide blood) and consent will be requested for collection of health information. Family members of deceased patients with cardiomyopathy or other inherited cardiac conditions may be asked if they wish to donate stored samples that may have been taken prior to death or as part of a post-mortem examination to establish cause of death. Any discussion with regard to the use of stored samples for this project will be initiated by the clinical care team for the deceased patient and their family to minimise any potential distress to the family. Sub-sets of patients may be asked to donate tissue samples taken as part of their clinical care.
How this trial compares with your answers
Answer 2 more questions to improve match
What we know so far
Still need:
- • Tell us your age for better matching
- • Tell us your sex for better matching
Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.
Eligibility at a Glance
Key info
- Age: Not specified
- Who can join: All genders
Biomarkers mentioned
What the study is looking for
- ✓Males or females with a confirmed diagnosis of childhood onset (\<16 years) PCM
- ✓Males or females with childhood onset (\<16 years) of a rare inherited heart condition likely to be a monogenic...
- ✓Capacity for parents to provide agreement to take part
- ✓Genotype negative following local standard diagnostic ICC gene panel
- ✓Family members of patients with ICC, both affected and unaffected
Who cannot take part
- ✗Parents who lack capacity to provide consent on behalf of their children/themselves
- ✗Onset over 16 years
- ✗Significant teratogen exposure (including maternal diabetes) likely to contribute to heart dysfunction (following...
- ✗Significant coronary heart disease likely to contribute to heart dysfunction (following discussion with Cardiologist)
- ✗Other secondary causes of heart dysfunction likely to explain the phenotype of the patient
See the full criteria
Where Is This Study? (3 UK sites)
Royal Brompton Hospital
London SW3 6NP, United Kingdom
Great Ormond Street Hospital for Children
London, United Kingdom
Harefield Hospital
Uxbridge UB9 6JH, United Kingdom
How to Get in Touch
Katherine Josephs
Sponsor contactCONTACT
Chief Investigator
Sponsor contactCONTACT
